Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.
Joly F, Delva R, Mourey L, Sevin E, Bompas E, Vedrine L, Ravaud A, Eymard JC, Tubiana-Mathieu N, Linassier C, Houede N, Guillot A, Ringensen F, Cojocarasu O, Valenza B, Leconte A, Lheureux S, Clarisse B, Oudard S.
Joly F, et al. Among authors: eymard jc.
BJU Int. 2015 Jan;115(1):65-73. doi: 10.1111/bju.12552.
BJU Int. 2015.
PMID: 24180479
Clinical Trial.